Medtronic (MDT) News Today

Medtronic PLC (MDT): Shares have risen recently amid favorable coverage proposals and early pipeline progress. Key developments for investors include:

• Positive Sentiment: CMS proposed Medicare coverage for Medtronic’s renal denervation therapy for high blood pressure, moving the treatment closer to broad patient access and driving investor optimism. Medtronic Stock Is Climbing Friday: What’s Going On?
• Positive Sentiment: Medtronic treated the first patient in a multi-organ denervation study for high blood pressure, highlighting progress in its cardiovascular pipeline. Medtronic treats first patient in multi-organ denervation study for high blood pressure
• Positive Sentiment: An article names Medtronic among top high-yield medical device stocks to consider, underscoring its attractive dividend profile for income-seeking investors. The Best High Yield Medical Device Stock to Invest $1,000 in Right Now
• Positive Sentiment: Medtronic is highlighted among healthcare dividend picks, drawing attention to its solid payout and stable cash flow. What Is Considered a Good Dividend Stock? 3 Healthcare Stocks That Fit the Bill
• Neutral Sentiment: J.P. Morgan maintained a Hold rating on MDT, citing both growth potential and execution challenges in its renal denervation program. Medtronic’s Renal Denervation Opportunity: Hold Rating Amid Challenges and Potential Growth
• Neutral Sentiment: BTIG reiterated a Hold rating for Medtronic, noting balanced growth opportunities against competitive and reimbursement risks. Medtronic’s Market Position: Balancing Growth Opportunities and Challenges
• Negative Sentiment: The FDA issued an early alert concerning Medtronic’s pH monitoring capsules, potentially flagging safety or performance issues that could affect product sales and regulatory scrutiny. FDA Issues Early Alert for Medtronic pH Monitoring Capsules